These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22492267)

  • 1. QTc prolongation and clozapine: fact or artefact?
    Nielsen J
    Aust N Z J Psychiatry; 2012 Aug; 46(8):793-4. PubMed ID: 22492267
    [No Abstract]   [Full Text] [Related]  

  • 2. Clozapine rechallenge following QTc prolongation.
    Law D; Mohan T; Bastiampillai T; Dhillon R
    Aust N Z J Psychiatry; 2014 Feb; 48(2):198-9. PubMed ID: 23881080
    [No Abstract]   [Full Text] [Related]  

  • 3. Usefulness of heart rate variability (HRV) for monitoring clozapine plasma levels.
    Agelink MW; Sayar K; Klieser E
    Pharmacopsychiatry; 2003 Jul; 36(4):166-7; authors reply 168. PubMed ID: 12905104
    [No Abstract]   [Full Text] [Related]  

  • 4. Clozapine, elevated heart rate and QTc prolongation.
    Kim DD; White RF; Barr AM; Honer WG; Procyshyn RM
    J Psychiatry Neurosci; 2018 Jan; 43(1):71-72. PubMed ID: 29252168
    [No Abstract]   [Full Text] [Related]  

  • 5. Improvement in QTc prolongation induced by zotepine following a switch to perospirone.
    Suzuki Y; Watanabe J; Sugai T; Fukui N; Ono S; Tsuneyama N; Saito M; Someya T
    Psychiatry Clin Neurosci; 2012 Apr; 66(3):244. PubMed ID: 22443250
    [No Abstract]   [Full Text] [Related]  

  • 6. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment.
    Grande I; Pons A; Baeza I; Torras Á; Bernardo M
    Hum Psychopharmacol; 2011 Aug; 26(6):397-403. PubMed ID: 21826738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia.
    Sankaranarayanan A; Kazi S; Andrade C
    Schizophr Res; 2024 Jun; 268():145-149. PubMed ID: 37770378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics.
    Lin CH; Chen MC; Wang SY; Lin CY
    J Formos Med Assoc; 2004 Jun; 103(6):437-41. PubMed ID: 15278188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iloperidone: a clinical overview.
    Citrome L
    J Clin Psychiatry; 2011; 72 Suppl 1():19-23. PubMed ID: 22217439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolongation of QTc interval and antipsychotics.
    Agelink MW
    Am J Psychiatry; 2002 Jun; 159(6):1063; author reply 1064. PubMed ID: 12042206
    [No Abstract]   [Full Text] [Related]  

  • 12. Antipsychotic-induced QTc interval prolongation.
    Dewan V; Roth BA
    Can J Psychiatry; 2004 Sep; 49(9):646. PubMed ID: 15503744
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of a method of clozapine dosage by selective electrode to the iodides.
    Teyeb H; Douki W; Najjar MF
    Drug Chem Toxicol; 2012 Jul; 35(3):272-6. PubMed ID: 21939364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia.
    Ozeki Y; Fujii K; Kurimoto N; Yamada N; Okawa M; Aoki T; Takahashi J; Ishida N; Horie M; Kunugi H
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):401-5. PubMed ID: 20079791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clozapine--the neglected potential].
    Munitz H
    Harefuah; 2012 May; 151(5):298-300, 318, 317. PubMed ID: 22844735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of treatment resistant schizophrenia unresponsive to clozapine.
    Barnes TR; McEvedy CJ; Nelson HE
    Br J Psychiatry Suppl; 1996 Dec; (31):31-40. PubMed ID: 8968653
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic drug monitoring-based clozapine dosing recommendations.
    Zernig G; Ng K; Hiemke C; Saria A
    Ther Drug Monit; 2007 Feb; 29(1):130-1. PubMed ID: 17304162
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
    Cook B; Hoogenboom G
    Australas Psychiatry; 2004 Mar; 12(1):74-6. PubMed ID: 15715745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine's role in the treatment of first-episode schizophrenia.
    Remington G; Agid O; Foussias G; Hahn M; Rao N; Sinyor M
    Am J Psychiatry; 2013 Feb; 170(2):146-51. PubMed ID: 23377634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.